For heavily treatment-experienced adults with HIV-1 failing therapy. See Full Indication.

Access the resources below for additional details about RUKOBIA, including the challenges of people living with multidrug-resistant (MDR) HIV-1 who are failing their current therapy, its mechanism of action, information about the BRIGHTE trial, dosing and drug interactions, and the full Prescribing Information.

BRIGHTE Long-Term Data for RUKOBIA

~5-Year* Efficacy Results

Hear from Dr. Tony Mills on the exciting long-term data for RUKOBIA

*Based on BRIGHTE 240-week data. 

BRIGHTE Educational Series

INTRODUCTION TO PEOPLE LIVING WITH MDR HIV-1 

Consider challenges faced by people living with multidrug-resistant (MDR) HIV-1 with multidrug resistance and limited antiretroviral (ARV) options

Video player requires JavaScript enabled. You can download this video here: /content/dam/cf-viiv/rukobia-hcp/master/videos/PM-US-FST-VID-200005%20HTE%20HiRes.mp4

NOVEL MECHANISM OF ACTION

Discover a first-in-class attachment inhibitor that prevents HIV-1 from interacting with host immune cells1

Video player requires JavaScript enabled. You can download this video here: /content/dam/cf-viiv/rukobia-hcp/master/videos/PM-US-FST-VID-200006%20MOA%20HiRes.mp4

DOSING AND DRUG INTERACTIONS

Review recommended dosing, considerations for coadministration, and contraindications with RUKOBIA

Video player requires JavaScript enabled. You can download this video here: /content/dam/cf-viiv/rukobia-hcp/master/videos/PM-US-FST-VID-200008%20Dosing%20HiRes.mp4

Downloadable Resource

Notepad

RUKOBIA PRESCRIBING INFORMATION

See the full Prescribing Information for RUKOBIA

References:

  1. Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.

FSTWCNT230016